KUR Stock Overview A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Kura Oncology, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Kura Oncology Historical stock prices Current Share Price US$8.57 52 Week High US$21.40 52 Week Low US$8.53 Beta 0.76 1 Month Change -16.75% 3 Month Change -50.34% 1 Year Change -32.55% 3 Year Change -33.08% 5 Year Change -31.47% Change since IPO 20.01%
Recent News & Updates
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting Dec 10
Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors Sep 17
Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist) Aug 08
Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Now 20% undervalued Jul 19 See more updates
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting Dec 10
Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors Sep 17
Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist) Aug 08
Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Now 20% undervalued Jul 19 Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index
Insufficient new directors Jul 01
New minor risk - Share price stability Jun 06
Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001 May 25
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML May 15
Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 27
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML Apr 23
Now 21% undervalued Apr 16
Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024 Apr 13
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma Mar 07
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia Feb 29
Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024 Feb 21
Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia Jan 30
New major risk - Share price stability Jan 24 Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC Jan 24
Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Nov 03
Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806 Oct 20
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer Sep 29
Kura Oncology Appoints Brian Powl as Chief Commercial Officer Aug 15
Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29 Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million. Jun 15
Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress Jun 12
Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023 May 04
Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 17
Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia Feb 10
Chief Medical Officer recently sold €56k worth of stock Feb 02
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor Jan 25
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib Dec 13 Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company, Nov 04
Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma Oct 27
Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 28
Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer Apr 09
Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
Kura Oncology, Inc. Announces Executive Changes Feb 03 Kura Oncology, Inc. Announces Executive Changes
Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia Jan 22
Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma Dec 17
Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma Dec 14
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia Nov 25
Independent Director Robert Hoffman has left the company Aug 05 Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539 Jun 25
New 90-day low: €22.00 Feb 26
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma Feb 25
Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day low: €24.40 Jan 28
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 At American Society of Hematology Annual Meeting Dec 06
New 90-day high: €29.40 Nov 07
Kura Oncology, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
Kura Oncology, Inc. Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Ka Inhibitor in Head and Neck Squamous Cell Carcinoma Oct 29
New 90-day high: €26.40 Oct 08 Kura Oncology, Inc. to Report Q1, 2020 Results on May 04, 2020
New 90-day high: €24.80 Sep 19
New 90-day high - €18.50 Aug 26
New 90-day high - €17.50 Aug 10 Shareholder Returns KUR DE Biotechs DE Market 7D -1.2% 1.2% -0.3% 1Y -32.6% -14.3% 7.0%
See full shareholder returns
Return vs Market: KUR underperformed the German Market which returned 7% over the past year.
Price Volatility Is KUR's price volatile compared to industry and market? KUR volatility KUR Average Weekly Movement 9.2% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: KUR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: KUR's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Show more Kura Oncology, Inc. Fundamentals Summary How do Kura Oncology's earnings and revenue compare to its market cap? KUR fundamental statistics Market cap €661.98m Earnings (TTM ) -€189.81m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) KUR income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$197.55m Earnings -US$197.55m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 07:33 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Kura Oncology, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays Jason Zemansky BofA Global Research Leah Rush Cann Brookline Capital Markets
Show 18 more analysts 
